(Q33835954)

29 July 2017

1 reference

title

Integrating radiation therapy in the curative management of ovarian cancer: current issues and future directions (English)

1 reference

adaptive radiation therapy

29 July 2017

main subject

0 references

1 reference

Cardenes H

1

1 reference

29 July 2017

Randall ME

series ordinal

2

1 reference

29 July 2017

publication date

1 January 2000

1 reference

Seminars in Radiation Oncology

29 July 2017

published in

1 reference

29 July 2017

volume

10

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

61-70

1 reference

Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Current concepts in cancer: ovary--treatment of stages III and IV. Choice of postoperative therapy based on prognostic factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Abdominopelvic radiotherapy in ovarian cancer. A 10-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Testing the validity of a prognostic classification in patients with surgically optimal ovarian carcinoma: a 15-year review

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

High-risk early-stage ovarian cancer. Randomized clinical trial comparing cisplatin plus cyclophosphamide versus whole abdominal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

The role of adjuvant therapy in Stage I ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Treatment of epithelial carcinoma of the ovary: operation, irradiation, and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Postoperative abdominopelvic radiation therapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Determinants of survival of patients with epithelial ovarian carcinoma following whole abdomen irradiation (WAR).

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Analysis of postoperative radiation therapy in stage I through III epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Intraperitoneal radioactive phosphorus therapy in ovarian carcinoma. Analysis of 313 patients treated primarily or at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Platinum plus cyclophosphamide plus radiotherapy is superior to platinum alone in 'high-risk' epithelial ovarian cancer (residual negative and either stage I or II, grade 3, or stage III, any grade).

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Postoperative radiation therapy for epithelial ovarian cancer: the curative role based on a 24-year experience

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked stage I, II, and III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

A standard dose of radiation for "microscopic disease" is not appropriate

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Analysis of complications in patients treated with abdomino-pelvic radiation therapy for ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Effect of filgrastim (G-CSF) during chemotherapy and abdomino-pelvic radiation therapy in patients with ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Whole abdominal irradiation following chemotherapy in advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Stage III ovarian carcinoma: an analysis of treatment results and complications following hyperfractionated abdominopelvic irradiation for salvage

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Correlation between response to cisplatinum-combination chemotherapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Collateral resistance to photon and neutron irradiation is associated with acquired cis-platinum resistance in human ovarian tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Risk of leukemia after platinum-based chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Concomitant whole-abdominal radiation and intraperitoneal chemotherapy in advanced ovarian carcinoma. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

A phase I study of weekly cisplatin and whole abdominal radiation for the treatment of stage III and IV endometrial carcinoma: a Gynecologic Oncology Group pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

Taxol as a radiation sensitizer: a flow cytometric study.

1 reference

https://api.crossref.org/works/10.1016%2FS1053-4296%2800%2980022-3

7 January 2021

10.1016/S1053-4296(00)80022-3

Identifiers

DOI

1 reference

29 July 2017

1 reference